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Abstract
Introduction: Though coronavirus disease 2019 (COVID-19) is predominantly a respiratory 
illness, a growing number of studies reported gastrointestinal (GI) symptoms among these pa-
tients. We examined the incidence of GI symptoms in patients with COVID-19 and the GI symp-
toms as the initial presentation of the disease.
Methods: We examined peer reviewed studies in English of patients with COVID-19 that re-
ported GI symptoms. We searched PubMed and Google Scholar for articles published up to 
June 30, 2020 by using the keywords ‘COVID-19’, ‘Coronavirus’, severe acute respiratory syn-
drome coronavirus 2 ‘SARS-CoV-2’, ‘gastrointestinal tract’, ‘gastrointestinal diseases’, ‘gastro-
intestinal symptoms and signs’. Studies with less than 30 patients and also those studies that 
did not report nausea, vomiting and diarrhea were excluded. 
Results: We reviewed 26 studies that reported GI symptoms among patients with COVID-19. 
Twenty-three studies were from China and the three remaining studies were from three different 
countries: US, France and South Korea. The mean age of patients was 47.2 years and 50.3% 
were females. From a total of 7,212 patients, 672 patients had nausea or/and vomiting (8.7%) 
and 732 (9.5%) had diarrhea. 6.8% of patients had GI symptoms as the initial presentation of 
COVID-19. 
Conclusion: GI symptoms are not common in COVID-19 patients. However, the recognition of 
GI symptoms may significantly help in implementing steps for preventing SARS CoV-2 trans-
mission. Testing for COVID-19 in patients presenting with only GI symptoms may help detect 
and prevent spreading of the COVID-19. 
Introduction
COVID-19 has been reported primarily as a respiratory illness, however patients with 
COVID-19 also have GI symptoms such as nausea, vomiting, diarrhea, and abdominal 
pain. [1,2] Interestingly the first case of COVID-19 reported in the US developed vom-
iting and diarrhea 4-6 days after the onset of the fever and respiratory symptoms. [3] 
Subsequent stool tests detected SARS CoV-2. The GI tract is the target of the SARS CoV-
2 given that the cell membrane angiotensin-converting enzyme 2 (ACE-2); which is the 
SARS CoV-2 receptor, is present in the enterocytes of the small and large intestine.
A recent systematic review from studies published until March 30, 2020 reported that 
12% of patients with COVID-19 have GI symptoms. [4] There is a growing literature of 
COVID-19 associated with GI involvement and many questions with pending answers. 
There is a need for the clinical characterization of the GI symptoms of patients with 
COVID-19. In this regard, it remains to be determined the severity, incidence and types 
of presentations of the GI symptoms among patients with COVID-19. A characterization 
of the GI symptoms of patients with COVID-19 will guide physicians to deliver the opti-
mal medical management of these patients. 
In an effort to characterize the GI clinical symptoms of patients with COVID-19, we re-
viewed the English literature to determine the incidence of GI symptoms of patients 
with COVID-19 and to determine how many patients presented initially with GI symp-
Recommended Citation:
Abbas, Mohammed; ElBeblawy, Rafik; Gadel-
moula, Islam; Rekha, Survarna; Sinanova, 
Bettina; and Bordon, Jose (2020). “Gastro-
intestinal Symptoms in Patients with COV-
ID-19,” The University of Louisville Journal of 
Respiratory Infections: Vol. 4, Iss. 1, Article 62. 
Received Date: August 25, 2020
Accepted Date: September 4, 2020
Published Date: September 30, 2020
Copyright: © 2020 The author(s). This origi-
nal article is brought to you for free and open 
access by ThinkIR: The University of Louis-
ville’s Institutional Repository. For more infor-
mation, please contact thinkir@louisville.edu. 
This article is distributed under the terms of the 
Creative Commons Attribution 4.0 Internation-
al License (CC BY 4.0), which permits unre-
stricted use, distribution, and reproduction in 
any medium, provided the original author and 
source are credited.
Funding Source: The author(s) received no 
specific funding for this work.
Conflict of Interest: All authors declared no 
conflict of interest in relation to the main objec-
tive of this work.
Gastrointestinal Symptoms in Patients with COVID-19
Mohammed Abbas1*; Rafik ElBeblawy1; Islam Gadelmoula1; Suvarna Rekha2; Bettina Sinanova2; Jose Bordon1,2
1Center of Excellence for Research in Infectious Diseases, Division of Infectious Diseases, University of Louisville School of Medicine, Louisville, KY, USA, 2Washington Health Institute , Washington, 
DC, USA
*mka.abbas@louisville.edu
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/62 2
ULJRI Gastrointestinal Symtoms in Patients with COVID-19
toms only or the GI symptoms associated with other symptoms.
Methods
Study design
This was a secondary analysis of studies published in English language of peer-reviewed journals on COVID-19 associ-
ated with GI symptoms. 
Database Search Strategies
We searched PubMed and Google Scholar for articles up to June 30, 2020. We used the following keywords in our 
search, ‘COVID-19’, ‘Coronavirus’, ‘SARS-CoV-2’, ‘gastrointestinal tract’, ‘gastrointestinal diseases’, ‘gastrointestinal 
symptoms and signs’.
Inclusion criteria
Peer review studies on COVID-19 that reported GI symptoms in the English language.  
Exclusion criteria
Scientific studies with a patient count below 30 and those studies that did not report nausea, vomiting, and diarrhea. 
After reviewing the articles, we included 26 studies for analysis. Institutional review board approval was not required 
given this study did not involve direct human participant research.
Results
Studies Included in Study
A total of 26 studies reported GI symptoms among patients with COVID-19 (Table 1). [5-30] Twenty-one studies were 
not included according to the exclusion criteria. All included studies were retrospective or case series. Twenty-three 
studies were from China and the 3 remaining studies were from three different countries: US, France and South Korea. 
The mean age of patients was 47.2 years and 50.3 % were female.
Incidence of GI Symptoms among Patients with COVID-19 
The total patient count from all studies was 7,212. Out of all patients, 672 had nausea or/and vomiting (8.7%) and 732 
(9.5%) patients had diarrhea.
Characterization of GI Symptoms among Patients with COVID-19
The most common GI symptoms were nausea or/and vomiting 8.7 %, and diarrhea 9.5 %. Other symptoms such as an-
orexia, constipation, and abdominal pain were rarely mentioned and therefore not included in our study.
Percent of Patients Initially Presenting with GI symptoms only
Our review revealed that 6.8% of patients had GI symptoms as the only or initial presentation of COVID-19 (Table 2).
Table 1. Incidence of Nausea, Vomiting and Diarrhea in COVID-19 patients.
Study
Characteristics of 
the total number of 
patients




Authors. Guan et al.(5)
Journal. N Engl J Med
Number of Patients. 1099
Country. China
Median Age: 47.0 
years (IQR 35-58)
Females 49.1%
55 (5)  42 (3.8)
Authors. Pan et al.(6)
Journal. Am J Gastroenterol
Number of Patients. 204
Country. China
Mean Age: 52.9 years 
(SD ± 16)
Females 47.5%
4 (2) 35 (17.1)
Authors. Zhou et al.(7)
Journal. N Engl J Med
Number of Patients. 149
Country. China
Median Age: 
56.0 years (IQR 
46·0–67·0)
Females 38%
7 (3.7) 9 (4.7)
Authors. Lu et al.(8)
Journal. N Engl J Med
Number of Patients. 171
Country. China
Median Age: 6.7 
years (Range 1-15)
Females 39.2%
11 (6.4) 15 (8.8)
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Study
Characteristics of 
the total number of 
patients




Authors. Yang et al.(9)
Journal. J Infect
Number of Patients. 149
Country. China
Mean Age: 45.1 years 
(SD ± 13.35)
Females 45.6%
11 (7.4)  2 (1.3)
Authors. Zhang et al.(10)
Journal. Allergy
Number of Patients. 140
Country. China
Median Age: 57.0 
years (Range 25-87)
Females 49.3%
31 (22.1) 18 (12.9)
Authors. Wang et al.(11)
Journal. JAMA
Number of Patients. 138
Country. China
Median Age: 56.0 
years (IQR 42-68)
Females 45.7%
19 (13.8) 14 (10.1)
Authors. Liu et al.(12)
Journal. Chin Med J (Engl)
Number of Patients. 137
Country. China
Median Age: 57.0 
years (Range 20-83)
Females 55.5%
0 (0) 11 (8)
Authors. Zhao et al.(13)
Journal. AJR Am J
Number of Patients. 101
Country. China




Authors. Chen et al.(14)
Journal. Lancet
Number of Patients. 99
Country. China
Mean Age: 55.5 years 
(Range 21-82)
Females 32.3%
1 (1) 2 (2)
Authors. Xu et al.(15)
Journal. Eur J Nucl Med Mol Imaging
Number of Patients. 90
Country. China
Median Age: 50 years 
(Range 18-86)
Females 57%
7 (7.8) 5 (5.6)
Authors. Shi et al.(16)
Journal. Lancet Infect Dis
Number of Patients. 81
Country. China
Mean Age: 49.5 years 
(Range 25–81)
Females 48%
4 (4.9) 3 (3.7)
Authors. Wu et al.(17)
Journal. Clin Infect Dis
Number of Patients. 80
Country. China
Median Age: 46.1 
years (SD 15.42)
Females 51.3%
1 (1.3) 1 (1.3)
Authors. Chen et al.(18)
Journal. J Med Virol
Number of Patients. 42
Country. China
Median Age: 51 years 
(IQR 42.75-62)
Females 64.3%
7 (16.7) 7 (16.7)
Authors. Wei et al.(19)
Journal. Clin Gastroenterol Hepatol
Number of Patients. 84
Country. China
Median Age: 37 years 
(Range 24-74)
Females 66.7%
22 (26.2) 26 (31)
Authors. Lin et al.(20)
Journal. Gut
Number of Patients. 95
Country. China
Mean Age: 45.3 years 
(SD- 18.3)
Females 52.6%
21 (22.1) 23 (24.2)
Authors. Song et al.(21)
Journal. Radiology
Number of Patients. 51
Country. China
Mean Age: 49.0 years 
(Range 16-76)
Females 51%
3 (5.9) 5 (9.8)
Authors. Han et al.(22)
Journal. Am J Gastroenterol
Number of Patients. 206
Country. China
Mean Age: 62.5 years 
(Range 27 to 92)
Females 55.8%
24 (11.7) 67 (32.5)
Authors. Nobel et al.(23)
Journal. Gastroenterology
Number of Patients. 278
Country. USA
Females 48% 63 (22.7) 56 (20.1)
Authors. Luo et al.(24)
Journal. Clin Gastroenterol Hepatol
Number of Patients. 1141
Country. China
Females 44% 204 (17.9) 69 (6)
Authors. Jin et al.(25)
Journal. Gut
Number of Patients. 651
Country. China
Mean Age: 46.1 years 
(SD 14.19)
Females 50%
21 (3.2) 53 (8.1)
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Discussion
Included Studies that Reported GI Symptoms Among Patients with COVID-19.
This review included 26 studies of patients with COVID-19 and GI symptoms published up to June 30, 2020. Most of 
the studies were from China and had a relatively small number of patients. A similar review to ours included 29 studies 
published until March 30, 2020. [4] Preprint publications were not included in our review. In an effort to maximize the 
data quality, our review included only peer reviewed articles in English. 
Study
Characteristics of 
the total number of 
patients




Authors. Park et al.(26)
Journal. Clin Gastroenterol Hepatol
Number of Patients. 46
Country. Korea
Median Age: 26 years 
(Range 18 to 57)
Females 54%
1 (2.2) 7 (15.2)
Authors. Lian et al.(27)
Journal. Influenza Other Respir Viruses
Number of Patients. 465
Country. China
Median Age: 45 years 
(Range 5 to 88)
Females 47.7%
22 (4.7) 36 (7.7)
Authors. Klopfenstein et al.(28)
Journal. Clin Res Hepatol Gastroenterol
Number of Patients. 114
Country. France
Median Age: 56 years 
(SD 18)
Females 58%
34 (29.8) 55 (48.2)
Authors. Zhang et al.(29)
Journal. Dig Liver Dis
Number of Patients. 504
Country. China
Mean Age: 51.2 years 
(SD 17.2)
Females 54.9%
40 (7.9) 62 (12.3)
Authors. Zheng et al.(30)
Journal. J Med Virol
Number of Patients. 1320
Country. China
Median Age: 50 years 
(IQR 40-57)
Females 56.1%
57 (4.3) 107 (8.1)
Total number of patients. 7212 Females 50.3% 672 (8.7) 732 (9.5)
Study
Characteristics of 




Authors. Pan et al.(6)
Journal. Am J Gastroenterol
Number of Patients. 204
Country. China




Authors. Wang et al.(11)
Journal. JAMA
Number of Patients. 138
Country. China




Authors. Liu et al.(12)
Journal. Chin Med J (Engl)
Number of Patients. 137
Country. China




Authors. Chen et al.(14)
Journal. Lancet
Number of Patients. 99
Country. China




Authors. Lin et al.(20)
Journal. Gut
Number of Patients. 95
Country. China




Total number of patients. 673 45 (6.7)
Table 2. Number of COVID-19 cases presented initially with GI symptoms only.
D: Number of patients with Diarrhea
N/V: Number of patients with Nausea/Vomiting
GI symptoms: Number of COVID-19 cases presented initially with GI symptoms only
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Incidence of GI Symptoms in COVID-19 Patients and its Significance.
Our study examined 1,404 patients (19.5%) with GI symptoms from a total of 7,212 patients with documented COVID-19. 
Furthermore, our study revealed an incidence of 8.7% of nausea/vomiting and 9.5% diarrhea among patients with 
COVID-19. There has been a wide variation in the percentages of these symptoms in different studies. Parasa et al. 
reported an incidence of nausea and vomiting of 4.6% and diarrhea 7.4%. [4] The variation of incidence of the nausea, 
vomiting and diarrhea could be due to many factors such as failure to report these symptoms in the early months of the 
pandemic by patients and healthcare workers, the novelty of the disease, and lack of awareness of the possible relation-
ship between GI symptoms and the COVID-19. Overall, GI symptoms in COVID-19 were not common.
The presence of GI symptoms among COVID-19 patients can be explained by two mechanisms. First, the GI tract is 
abundant with ACE-2 receptors to which the virus binds and enters the cell. [31] This is similar to how the virus binds 
to the respiratory tract where it multiplies and causes symptoms. [10] This mechanism suggests that the virus may 
cause acute gastritis and/or enteritis, resulting in nausea, vomiting, and diarrhea. [25] The second mechanism is a re-
cent theory, through the ‘Gut-Lung Axis’. [32,33] Normally, the change in the microbiota and immune regulation of the 
digestive tract causes an indirect dysregulating effect on the respiratory tract and thus leads to lung infection. However 
recently, a study suggested that this axis could be bidirectional. [34] This means that lung microbiota may affect the gut 
microbiota composition, therefore leading to GI symptoms (Figure 1).
Another important observation seen in COVID-19 patients is that they can present with GI symptoms initially be-
fore the respiratory symptoms (Table 2). Therefore, it is important to report and inquire about GI symptoms to help 
identify infection and control the spread of the disease. Patients with GI symptoms should be isolated and tested for 
COVID-19 by polymerase chain reaction (PCR) from a respiratory swab. There is also evidence for fecal viral shedding 
in patients with COVID-19. [18,22,35] At this point, the stool testing for SARS CoV-2 may help with the early detection 
of COVID-19 patients presenting only with GI symptoms.
It is recommended that awareness is raised among healthcare workers and the general public regarding the important 
relationship between GI symptoms and COVID-19. To help make sure that an individual does not transmit the disease, 
people with these symptoms are advised to seek medical attention for appropriate evaluation and treatment. PCR test-
ing of patients with just GI symptoms for COVID-19 using respiratory swabs may also help with early detection of the 
disease and reduce the risk for disease spreading. Although PCR testing of stool samples is not approved yet, it could be 
used as another option for screening. Even when there are no risk factors, patient-isolation for a few days could be ben-
eficial until the test results are available, or the patient develops upper respiratory symptoms. To have a clearer picture, 
healthcare personnel need to document GI symptoms for COVID-19 patients whether at presentation or throughout 
the disease course. Special precautions should be extended to all individuals dealing with stool from patients with 
COVID-19.
Figure 1. Proposed Bidirectional Gut-Lung Axis
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Our review has some strengths and limitations. Some of the strengths are the inclusions of peer reviewed studies in 
English and inclusion of publications up to June 30, 2020. In relation to the limitations, most of these studies were pre-
dominantly from China and the relatively small number of patients per studies. Therefore, these results cannot be used 
to represent the worldwide population. In addition, only a handful of studies mentioned the patients that presented 
initially with GI symptoms only.
In conclusion, GI symptoms are not common in COVID-19 patients and the recognition of these symptoms may signifi-
cantly help in implementing steps for preventing disease transmission. It is essential to share this knowledge among 
the community, encourage the reporting and documentation of these symptoms. Testing for COVID-19 in patients pre-
senting with GI symptoms only may help detect and prevent spreading of the disease. More studies are needed to cap-
ture targeted data so that more accurate and precise outcomes can be drawn.
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